SHP2 inhibitors could target cancer cells, T lymphocytes, and macrophages simultaneously, and, thereby, could have significant activity in conjunction with anti-PD-1 and anti-PD-L1 antibodies (Table 2) [88]. Here, PTPN11 is linked to cancer.